Genmab — November 2020
-
Seems data from the NSCLC expansion is unlikely to be presented already, but aren't they compelled to present the data either at a conference or at least one of the medical journals? And if that's the case, I guess ASH would be no good as it's only hematology - but which conference would be a good guess for results then - something in May/June?
-
One of these
https://waset.org/oncology-conferences -
Reminder: https://events.bizzabo.com/GenmabCMD
-
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in R/R DLBCL https://clinicaltrials.gov/ct2/show/NCT04628494?term=NCT04628494&draw=2&rank=1
-
LYRA / Dara-CyBorD completed https://clinicaltrials.gov/ct2/history/NCT02951819?A=25&B=26&C=merged#StudyPageTop
-
another Dara label extension to follow shortly - Positive recommendations on extensions of indications Name of medicine Kyprolis INN carfilzomib
Marketing-authorisation holder Amgen Europe B.V. More information Kyprolis: Pending EC decision (Extension of existing indication to include combination of Kyprolis with daratumumab and dexamethasone) -
Kursen reagerer let negativ.
-
JvdW må op i tempo;-)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind